Children and the elderly (≥60 years of age) have the highest incidence of status epilepticus (SE). Because of their general health, elderly individuals are much more likely than younger (<60 years of age) persons to have more severe consequences from seizures. The incidence of SE is 15.5/100 000 in the 60-69 age group, 21.5/100 000 in the 70-79 age group and 25.9/100 000 in persons 80 and older. The most common cause in the elderly is acute symptomatic, with stroke and hypoxia the most frequent. The overall mortality of SE is quite high and occurs early, often within the first few days, and is related to the cause, with mortality of more than 80% in persons with anoxia. Although the cause of SE is an important factor in mortality, the aging body and brain may contribute to an unfavorable outcome. Treatment in the elderly is essentially the same as in younger adults with benzodiazepines (lorazepam, diazepam, clonazepam) and longer acting antiseizure drugs (phenytoin, fosphenytoin, valproate, levetiracetam, and lacosamide. At this time there are no evidence-based studies regarding Axis 2 (etiology) and Axis 4 (age). All current interventions for SE involve antiseizure drugs that were developed for treatment of chronic epilepsy. Treatments should be developed that are more specific for the various etiologies and involve drugs that work on the underlying cause of the SE.
| INTRODUCTION
Status epilepticus (SE) is a medical emergency that affects persons of all ages. The elderly (≥60 years of age) have the highest incidence of SE of any age group. 1 Because of their general health, elderly individuals are much more likely than younger (<60 years of age) persons to have more severe consequences from seizures. 2 SE is defined as a condition resulting either from failure of the mechanisms responsible for seizure termination, or from initiation of mechanisms that lead to abnormally prolonged seizures. 3 Four axes have been defined: (1) semiology, (2) etiology, (3) EEG correlates, and (4) age. 3 For this discussion, Axes 2 and 4 are most critical, but unfortunately most of the studies regarding SE were implemented before this classification was proposed and there is a lack of evidence for treatment and outcome.
As they can in younger adults, many types of seizures can present as SE in the elderly. Although convulsive SE is the most common, dramatic, and easily recognized presentation of this condition, other forms must be considered. Nonconvulsive SE is a term used to denote a range of conditions in which electrographic seizure activity is prolonged and results in alteration of mental status manifested by a confusional state or decreased level of consciousness. 4 In patients aged 60 or older admitted to the emergency department with confusion or altered mental status, approximately 16% have been found to have nonconvulsive SE. 5 This underscores the need confusional states. Continuous monitoring of EEG coupled with real-time graphic analysis (TRend EEG), if available, may be especially helpful. Of interest, nonconvulsive SE is very uncommon in younger adults and appears to be most relevant in the elderly. Nonconvulsive SE is common in hospitals and intensive care locations after convulsions have been controlled. Refractory SE and super-refractory SE are nonconvulsive and will be discussed in more detail by other presenters in this supplement. Continuous simple partial motor seizures, known also as Kozhevnikov's epilepsy, are most common in persons with focal structural lesions. Although very rare, absence epilepsy may occur as a late complication of idiopathic generalized epilepsy. 6 Psychogenic nonepileptic SE has been observed in elderly persons and can present a diagnostic and treatment dilemma. This discussion will be limited to convulsive SE, as it is the most dramatic and best-studied form of this condition in the elderly.
| INCIDENCE OF CONVULSIVE SE

IN ELDERLY
A number of studies have investigated the age distribution of the incidence of SE. It follows a U-shaped curve, similar to that seen for the incidence of epilepsy. In a prospective community-based study in Richmond, Virginia, the incidence of SE was high in the zero to 9 age group, decreased in the teen years, and then began to rise and was the highest in the 60 and older age group. 7 This pattern was similar both in the tertiary care hospital and in the private practice community setting. 7 A similar age distribution has been reported in many studies from Europe and the United States. 8 The mean annual incidence of SE was estimated from the studies reviewed to be 15.5/100 000 in the 60-69 age group, 21.5/100 000 in the 70-79 age group, and 25.9/100 000 in persons 80 or older. 8 Thus the incidence of SE continues to increase with advancing age.
| ETIOLOGY
In general, persons with SE fall into one of 2 groups: those with preexisting epilepsy who develop SE, and those who have not had any seizures prior to the SE. 8 The cause of SE varies with age. In one review compiled from the literature, adults were compared with elderly adults. 8 The most striking difference was stroke, which was the cause of SE in 52.3% of elderly adults compared to 17.7% in adults. In the elderly, withdrawal from antiseizure medications and alcohol-related SE was much less common as a cause.
Comparisons for causes of SE are shown in Table 1 . 
| MORTALITY
The overall mortality of SE is quite high and occurs early, often within the first few days. In one study, mortality 30 days after the onset of SE was 31% in the university hospital population and 27% in the community setting. 7 Mortality is age-dependent, lowest in the young and highest in the elderly. A population-based study found that overall mortality was 13% in young adults, increased to 38% in the 60-79 age group, and was up to 50% in those 80 years or older. 9 A major factor in age-related mortality is the etiology (Axis 2) of SE. Mortality is more than 80% in persons with anoxia as the cause of SE, and more than 50% if the cause is hypoxia. 7 Many persons with anoxia/ hypoxia develop refractory or super-refractory SE and need treatment in the intensive care unit. But mortality in the elderly from other causes is also high. In a study from Finland that excluded persons with postanoxic etiologies, 1-year mortality rates were 22% for patients with refractory SE and 36% for patients with super-refractory SE. Age was a significant factor, as mortality was 63% in patients aged over 75 years with super-refractory SE. 10 Although the cause of SE is an important factor in mortality, the aging brain itself may contribute to an unfavorable outcome. A study of age-dependent mortality in the pilocarpine model of SE was informative in this regard. 11 SE was induced in 6 groups of rats aged 5, 7, 10, 15, 18, and 28 weeks. Severity of SE was evaluated by analysis of spike frequency, and there was no significant difference in this measure among the age groups. In addition, there was no difference in average time from the first seizure to SE. Thus there was no correlation between the age of animals
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and severity of SE. No deaths occurred in 5-week-old animals, but mortality due to SE increased progressively with age and was 90% in 28-week-old animals. The odds of mortality in the older (15-, 18-, and 28-week group) rats was 11.3 times higher than in the younger (5-, 7-, and 10-week group). With increasing age, mortality occurred earlier after the onset of SE. 11 Thus in addition to the etiology of SE, the intrinsic susceptibility of the aging subject must be considered. Some of this may reflect diminished cardiovascular reserve as well as changes in the aging brain.
| TREATMENT
SE requires urgent symptomatic treatment. Because SE results either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures, treatment must be directed at these factors. Unfortunately, few studies of the outcome of treatment of SE have evaluated for Axis 4, age. In general, treatment of the elderly has followed the same regimens as treatment for the younger age groups. Intravenous benzodiazepines (lorazepam, diazepam, clonazepam) and intramuscular midazolam are the most common treatments for early SE. These drugs have a relatively short half-life. If these fail, the patient may be considered to be in benzodiazepine-resistant SE or established SE. For established SE, intravenous antiseizure drugs (phenytoin, fosphenytoin, valproate, levetiracetam, phenobarbital, and lacosamide) are widely used. Unfortunately, there are very few controlled studies addressing the relative efficacy of these treatments, especially for the elderly. The major evidence that serves as the basis for many protocols is a randomized, double blind, multicenter trial of 4 intravenous regimens: diazepam (0.15 mg/kg of body weight) followed by phenytoin (18 mg/ kg), lorazepam (0.1 mg/kg), phenobarbital (15 mg/kg), and phenytoin (18 mg/kg). 12 Over the past 25 years, major advances in definition, classification, and understanding of the mechanisms underlying SE have been achieved. 13 Despite this, up to 40% of patients in early SE cannot be controlled with first-line drugs. The treatment of super-refractory status is still an almost evidence-free zone. At this time there are no evidence-based studies regarding Axis 2 (etiology) and Axis 4 (age). The safe use of intravenous phenytoin was established during [1975] [1976] in an open label evaluation in which an infusion rate of 50 mg/min was found to not be associated with hypotension in younger adults.
14 However, the rate had to be slowed with advancing age, but the full loading dose could be delivered during all but one of the 159 infusions.
14 Because of its pH of 12 and high levels of propylene glycol, intravenous phenytoin remains a drug than needs to be administered with caution, including monitoring of blood pressure. 14 A much more water soluble formulation, fosphenytoin, may be administered more safely and has the advantage of being able to be administered intramusculary. 15 All current interventions for SE involve antiseizure drugs that were developed for treatment of chronic epilepsy. However, it is likely that SE involves mechanisms that differ from those involved in isolated seizures that are usually of limited duration. Novel approaches are needed. One new approach may involve γ-aminobutyric acid A (GABA A ) receptor positive allosteric modulator neuroactive steroids such as allopregnanolone that potentiate extrasynaptic GABA A receptors when the benzodiazepines have lost their effectiveness. 16 To increase the introduction of novel drugs for the treatment of human SE, studies using naturally occurring canine SE as a Central nervous system infection 2. translational platform could obtain information such as cardiovascular side effects not obtainable from small animals. 17 
| CONCLUSIONS
The treatment of SE has advanced very little in the last 40 years due to the barriers imposed by regulations regarding informed consent. With the exception of one study by Treiman's group, 12 the antiseizure drugs used have not been studied in well-controlled situations. Most studies of outcome have not been stratified according to Axis 2 (etiology) or Axis 4 (age). Thus the current treatment of SE in the elderly has many shortcomings. It is obvious that the elderly are more frail and have more comorbidities than younger adults with SE, but at this time we do not have evidence for the following: how should drugs be managed differently once status has ended; do elderly patients need a different approach; are they at greater risk from aggressive treatment than younger individuals; and should they be transitioned to other agents that are preferred in the aged quickly? There are no studies about long-term prognosis after SE and how this might be different from the younger. What is known is that mortality increases with age. Future efforts need to be directed at performing more well-controlled studies to determine which of the current drugs provide the best efficacy and safety profile for the elderly as distinct from the profile for the younger adults. In addition, treatments should be developed that are more specific for the various etiologies and involve drugs that work on the underlying cause of the SE. Very likely the best treatments for anoxia/hypoxia will differ from treatments for stroke-or hemorrhage-caused SE. These may involve use of drugs in categories other than antiseizure agents. In addition, novel drugs that are specific for dealing with the factors that cause seizures to be prolonged need to be developed, separate from drugs for chronic epilepsy. Suggested characteristics for an ideal anti-SE drug for the elderly are listed in Table 2 .
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